Try our beta test site

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma (REGAL)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: October 20, 2008
Last updated: November 7, 2016
Last verified: October 2016
The purpose of this study is to see how effective cediranib is in treating a brain tumour called recurrent glioblastoma. Two drugs are being tested in this study. Lomustine is an approved oral chemotherapy that belongs to the class of drugs called alkylating agents. Cediranib is a new drug that has not yet been approved for this disease. This study will compare the use of lomustine with cediranib, cediranib alone or lomustine with placebo ("inactive substance") to see whether the combination or cediranib alone will be more effective than the chemotherapy alone (lomustine) in preventing the growth of cancer cells.

Condition Intervention Phase
Recurrent Glioblastoma
Drug: Cediranib
Drug: Lomustine Chemotherapy
Drug: Placebo Cediranib
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Baseline at 6 weeks and then every 6 weeks to discontinuation ]

    For patients with measurable disease at entry (at least one lesion that has a shortest diameter

    ≥10 mm at baseline on 2 axial slices), PFS will be defined as the earliest time that:

    1. The sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions has increased by a greater than or equal to 25% in comparison to the nadir scan as long as the shortest diameter is ≥15 mm. If the dose of steroids has been reduced within the 10 days prior to the scan being conducted, progression will be based on a follow-up scan performed after the dose of steroids has been stabilized for 10 days.
    2. The patient has died from any cause.
    3. A new lesion is detected that is outside the original tumor volume and has a shortest diameter ≥10 mm.

Secondary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Baseline through to date of death up to 25th April 2010 ]
    Number of months from randomisation to the date of death from any cause

  • Response Rate [ Time Frame: Baseline at 6 weeks and then every 6 weeks to discontinuation ]

    An individual visit response of PR was defined as a greater than or equal to 50% reduction in the sum of the products of the largest perpendicular diameters of contrast enhancement for all lesions compared to baseline as long as the steroid dose has not been increased within the previous 10 days and no new lesions are present.

    An individual visit response of CR was defined as the complete disappearance of all tumor on MRI scan.

  • Alive and Progression Free Rate at 6 Months (APF6) [ Time Frame: 6 Months ]
    Proportion of patients alive and progression free at 6 months (based on central review) as estimated from Kaplan-Meier techniques. Values are percentages.

  • Daily Steroid Dose [ Time Frame: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assed up to 2014-April-25 ]
    The mean steroid dosage prior to treatment will be considered as the patient's baseline. The percent change in average daily steroid dosage from baseline is calculated by following formula: PC = (md - bm)/bm*100; where PC is the percent change in average daily steroid dosage from baseline; md the mean daily steroid dosage recorded from the first day of therapy to progression; and bm the baseline mean.

  • Steroid Free Days [ Time Frame: Baseline to the date of first documented progression or date of death or study discontinuation, whichever came first, assessed up to 2014-April-25 ]
    Number of days known not to have used any steroids prior to progression

Enrollment: 423
Study Start Date: October 2008
Study Completion Date: September 2016
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cediranib 30mg
Cediranib 30mg
Drug: Cediranib
30 mg/day, oral, until progression
Cediranib 20mg + lomustine
Cediranib 20mg + lomustine
Drug: Cediranib
20 mg/day, oral, until progression
Drug: Lomustine Chemotherapy
110 mg/m2 / Q6W, oral, until progression
Active Comparator: Lomustine and Placebo Cediranib
Lomustine and Placebo Cediranib
Drug: Lomustine Chemotherapy
110 mg/m2 / Q6W, oral, until progression
Drug: Placebo Cediranib
Oral, until progression


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmation of recurrent glioblastoma
  • Life expectancy ≥ 12 weeks
  • Received only one prior systemic chemotherapy regimen and this regimen must contain temozolomide

Exclusion Criteria:

  • Patients on enzyme-inducing anti-epileptic drugs within 3 weeks prior to randomisation
  • Poorly controlled hypertension
  • Previous anti-angiogenesis (eg bevacizumab, sorafenib, sunitinib) therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00777153

  Hide Study Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, Arizona
Research Site
Pheonix, Arizona, United States
United States, California
Research Site
Los Angeles, California, United States
United States, Connecticut
Research Site
New Haven, Connecticut, United States
United States, Florida
Research Site
Gainesville, Florida, United States
Research Site
Jacksonville, Florida, United States
United States, Illinois
Research Site
Chicago, Illinois, United States
Research Site
Evanston, Illinois, United States
United States, Kansas
Research Site
Kansas City, Kansas, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, Michigan
Research Site
Detroit, Michigan, United States
United States, New York
Research Site
Amherst, New York, United States
Research Site
New York, New York, United States
United States, Ohio
Research Site
Cincinnati, Ohio, United States
Research Site
Cleveland, Ohio, United States
Research Site
Columbus, Ohio, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Pittsburgh, Pennsylvania, United States
United States, Texas
Research Site
Houston, Texas, United States
United States, Washington
Research Site
Seattle, Washington, United States
United States, West Virginia
Research Site
Morgantown, West Virginia, United States
Research Site
Camperdown, Australia
Research Site
Heidelberg, Australia
Research Site
Nedlands, Australia
Research Site
Parkville, Australia
Research Site
St Leonards, Australia
Research Site
Woodville, Australia
Research Site
Graz, Austria
Research Site
Brussels (Anderlecht), Belgium
Research Site
Brussels (Jette), Belgium
Research Site
Brussels (Woluwé-St-Lambert), Belgium
Research Site
Leuven, Belgium
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Canada, Ontario
Research Site
Toronto, Ontario, Canada
Canada, Quebec
Research Site
Montreal, Quebec, Canada
Czech Republic
Research Site
Liberec, Czech Republic
Research Site
Bobigny, France
Research Site
Marseille, France
Research Site
Paris cedex 13, France
Research Site
Rennes, France
Research Site
Saint Herblain, France
Research Site
Villejuif, France
Research Site
Berlin, Germany
Research Site
Bielefeld, Germany
Research Site
Dresden, Germany
Research Site
Düsseldorf, Germany
Research Site
Göttingen, Germany
Research Site
Hannover, Germany
Research Site
Heidelberg, Germany
Research Site
Kiel, Germany
Research Site
Leipzig, Germany
Research Site
Nordhausen, Germany
Research Site
Regensburg, Germany
Research Site
Amsterdam, Netherlands
Research Site
Den Haag, Netherlands
Research Site
Groningen, Netherlands
Research Site
Maastricht, Netherlands
Research Site
Rotterdam, Netherlands
United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Sutton, United Kingdom
Sponsors and Collaborators
Study Director: Jane Robertson AstraZeneca
Principal Investigator: Tracy Batchelor, MD, MPH Massachusetts General Hospital
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AstraZeneca Identifier: NCT00777153     History of Changes
Other Study ID Numbers: D8480C00055
Study First Received: October 20, 2008
Results First Received: April 3, 2012
Last Updated: November 7, 2016

Keywords provided by AstraZeneca:
Advanced Solid Tumour

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents processed this record on March 29, 2017